Log in with your email address username.


[Correspondence] Rifampicin in treating S aureus bacteraemia – Authors’ reply

As Siegbert Reig and colleagues state in their letter, the ARREST trial found that in adults with Staphylococcus aureus bacteraemia, 14 days of adjunctive rifampicin had no significant effect on the composite primary endpoint of death or microbiologically-confirmed failure or recurrence after 12 weeks.1 However, contrary to their subsequent statements, rifampicin had no effect on treatment failure, only on recurrence, and the significant association between rifampicin and antibiotic-modifying adverse events and drug interactions was in the intention-to-treat population, not in a subgroup.